研究单位:[1]Sichuan Cancer Hospital and Research Institute[2]Jiangsu HengRui Medicine Co.,Ltd.
研究目的:
The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC,and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC.